Structural studies on a congenital abnormal coagulation factor XII (Hageman factor), factor XII Washington D.C., have been performed to identify the defect responsible for its lack of procoagulant activity. Amino acid sequence analysis of a tryptic peptide isolated from the abnormal factor XII indicated that Cys-571 (equivalent to Cys-220 in the chymotrypsin numbering system) had been replaced by serine. No other substitutions in the active-site triad-namely, His-393, Asp-442, and Ser-544-were found. We propose that the Cys-571 -* Ser replacement found in this factor XII variant destroys the formation of the disulfide linkage between Cys-540 and Cys-571, giving rise to an altered conformation of the active-site serine residue or the secondary substrate-binding site and, thus, leads to the loss of enzyme activity.
Coagulation factor XII (Hageman factor) is a plasma protein that was originally found as a functionally deficient agent in plasmas from individuals with Hageman trait (1) . Under certain conditions, this protein appears to initiate several host defense plasma reactions, including blood coagulation, fibrinolysis, and kinin generation (2) (3) (4) . Human factor XII is a zymogen of a serine protease with an approximate Mr of 80,000 and consists of a single-chain glycoprotein composed of 596 amino acid residues (5-9). When normal blood comes into contact with negatively charged surfaces, such as glass, kaolin, dextran sulfate, and sulfatide, factor XII is bound to the surface and converted to an active enzyme (factor XIIa) by a complex reaction involving plasma prekallikrein and high-molecular-weight kininogen (2) (3) (4) (10) (11) (12) . Factor XII undergoes, on the surface, specific limited proteolysis by kallikrein and transforms into two active enzyme forms, a-factor XIIa (a-XIIa) and 8-factor XIIa (,B-XIIa). a-XIIa is composed of two polypeptide chains with Mr values of 52,000 and 28,000, whereas ,B-XIIa consists of two chains with Mr values of 2,000 and 28,000 (5) . The heavy chain of a-XIIa is composed of 353 amino acid residues and contains four different domains (6, 7) . The light chain of a-XIIa is a catalytic domain with 243 amino acid residues that contains the active-site triad of serine protease (5, 7) .
The plasma of the majority of subjects with Hageman trait also lacks immunologically identifiable factor XII. Very rare individuals with this disorder, however, whose plasma contains nearly normal amounts of nonfunctional but immunologically identifiable factor XII, have been reported (13) (14) (15) . Because these plasmas contain cross-reacting material (CRM) recognized by the specific antiserum, these cases have been called CRM+ (CRM-positive) variant. Studies of the nonfunctional factor XII in CRM+ Hageman trait may provide a unique opportunity to examine the structurefunction relationship of this plasma protein. One of the abnormal factor XII proteins from the plasma of an individual with CRM' Hageman trait (factor XII Washington D.C.) has been isolated and partially characterized (14) . This abnormal factor XII has the following properties: (i) it has the same molecular weight as normal factor XII, (ii) it shows no clot-promoting activity but does show the same specific antigenicity as purified normal factor XII in immunoassay, (iii) limited proteolysis of the abnormal factor XII exposed to a mixture of plasma and glass yields a two-chain a-XIIa with normal-sized heavy and light chains, and (iv) this abnormal factor XII is fragmented by trypsin in the same way as normal factor XII, but no prekallikrein-activating activity and no incorporation of [3H]diisopropyl phosphorofluoridate into a catalytic domain are observed. These results suggest that the abnormality in this enzyme resides at or near the active-site triad of the molecule.
The present study was undertaken to further elucidate the structural abnormality of factor XII Washington D.C. that would account for the functional impairment of the molecule. The results indicate that the impairment of the serine protease activity is due to replacement of Cys-571 with serine in the catalytic domain. (Fig. 1A) , and 45.9 min (Fig.  1B) , all peptides from both samples were obtained as a single peptide. The impure peptides were purified further by rechromatography as described, and the purified peptides were subjected to further analyses. The two chromatograms in Fig.  1 differ in some ways. Three peptides eluted at the retention time of 35.4 min (T1OC), 50.7 min (T12'), and 60.9 min (T9N) appeared only in the digest of abnormal 83-XII (Fig. 1B) , and also the heights of three peptide peaks eluted at the retention time of 40.5 min (T2C-3), 62.1 min (T2), and 66.0 min (T9) were greater than those of the digest of the normal control. Most differences between the two chromatograms in Fig. 1 , except for peptide T12', could be explained mainly by uneven digestion of S-pyridylethylated f-XII by trypsin. In the abnormal molecule, complete cleavage of the Arg-474-Pro-475 bond was seen, which yielded the peptides T8 and T9, whereas the extent of this cleavage was fairly reduced in the normal molecule. In addition, peptide bonds of Arg-398-Pro-399, His-393-Cys-394, Tyr-462-Val-463, Phe-507-Leu-508, and Met-527-Leu-528 were partially cleaved by trypsin in the abnormal molecule, generating the peptides T2, T2C-3, T8N, T9N, and T10C. One clear difference between A and B of Fig. 1 containing one cysteine and two serines, as expected from the sequence data (6, 7). However, the amino acid composition of peptide T12' derived from the abnormal g3-X11 showed one more seine and one less -pyridylethylcysteine than that of peptide T12. To determine the basis for this difference, sequence analysis of the aberrant peptide T12' was performed.
MATERIALS AND METHODS
Amino Acid Sequence of Aberrant Peptide T12'. The sequence of peptide T12' was determined with duplicate samples by automated Edman degradation. As shown in Table 2 , peptide T12' differed from the normal T12 peptide by a single amino acid at position 571-a cysteine in the normal peptide and a serine in the abnormal peptide. This result indicates that a Cys --+ Ser substitution at position 571 has shifted the retention time from 54 min for the normal peptide T12 to 52.8 min for the aberrant peptide T12'. The Cys --+ Ser substitution at position 571, on the other hand, has to provide a halfCys-540, because both cysteine residues correspond to the "&serine disulfide loop" found in chymotrypsin and other serine proteases. To confirm the free sulfhydryl group at position 540, abnormalB1-XII was S-pyridylethylated without any reduction. However, the sample after acid hydrolysis did Amino acid  T1  T2  T2-3 T2C-3  T5  T6  T7   T8  T9N  T9  T10 T10C T12' T13-14 PECys, S-Pyridylethylcysteine; ND, not determined; GalNH2, galactosamine. *Positions of each tryptic peptide from the abnormal -XII correspond to those taken from the amino acid sequence (6, 7). Peptide T12' was identified as an aberrant peptide derived from the abnormal ,3-XII.
not yield S-pyridylethylcysteine, indicating that Cys-540 must be a mixed disulfide form (data not shown). Among the tryptic peptides isolated from normal and abnormal 13-XII, three peptides-T7, T2-3, and T10-contained the functionally important residues Asp-102, His-57, Ser-195, Asp-189, and Asp-194 of a-chymotrypsin. Of these residues, the aspartate residue (Asp-102) in peptide T7 was identified by the direct Edman degradation method. Peptide T2-3, the peptide containing the active-site histidine DISCUSSION Collectively, the data described thus far make it very unlikely that the molecular abnormality of factor XII Washington D.C. is due to replacement of any amino acid residues associated directly with the active-site catalytic triad or the substrate-binding pocket. Therefore, the replacement of cysteine by serine at position 571 from the NH2 terminus of abnormal factor XII appears responsible for the loss of catalytic activity. Because the genetic codon for Cys-571 has been determined as TGT (7) (8) (9) 20) , we concluded that the patient's genomic DNA encoding for factor XII has a AGT or TCT nucleotide mutation.
Cys-571 (equivalent to Cys-220 in chymotrypsin) is a highly conserved amino acid residue among serine proteases, including pancreatic enzymes, blood coagulation factors, fibrinolytic enzymes, and complement factors. A reasonable assumption from the disulfide location in other serine proteases is that a disulfide linkage between Cys-540 and Cys-571 is formed in factor XII (5, 7) . Based on the crystallographic data for a bovine trypsin-pancreatic trypsin inhibitor comBiochemistry: Miyata et al.
Proc. Natl. Acad. Sci. USA 86 (1989) Factor)l Wwhhgton D.C. plex (21) , this disulfide bond is exposed on the surface, the so-called serine disulfide loop, and lies close to the specificity hole. Therefore, its integrity is probably important for enzyme activity. A comparison of the serine disulfide loop of normal factor XII with factor XII Washington D.C. is shown in Fig. 2 . This serine disulfide loop contains the active-site serine residue (Ser-195) and residues Ser-214-Trp-215-Gly-216. The peptide backbone of these residues is thought to interact with the side chains of the substrate to properly orient the bond that is to be cleaved (22, 23) . Therefore, we propose that the Cys -* Ser substitution found in this factor XII variant destroys the formation of disulfide linkage between Cys-540 and Cys-571 and may form a mixed disulfide bond between Cys-540 and a cysteine residue or a glutathione, altering conformation of the active-site serine residue or the secondary substrate-binding site, which leads to loss of the enzyme activity.
